Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Antibodies

Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Antibodies


November 1, 2012
6255 Pages - SKU: BIOS4910053
License type:
PDF E-mail From Publisher      US $5,175.00
Global Site License Fulfilled by Publisher      US $12,937.50
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:
  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.



More Oncology/Hematology reports by BioSeeker Group AB

Conjugated Drugs in Oncology: Drug Pathway Analyzer 2014 by BioSeeker Group AB
Conjugated Drugs in Oncology: Drug Pathway Analyzer 2014Extra value: One year of free online updates included with this productThere are today at least 262 conjugated ...
Biologicals in Oncology: Drug Pathway Analyzer 2014 by BioSeeker Group AB
Biologicals in Oncology: Drug Pathway Analyzer 2014Extra value: One year of free online updates included with this productThere are today at least 1421 biological drugs ...
Proteins in Oncology: Drug Pathway Analyzer 2014 by BioSeeker Group AB
Proteins in Oncology: Drug Pathway Analyzer 2014Extra value: One year of free online updates included with this productThere are today at least 353 protein drugs ...
Nucleic Acid Therapies in Oncology: Drug Pathway Analyzer 2014 by BioSeeker Group AB
Nucleic Acid Therapies in Oncology: Drug Pathway Analyzer 2014Extra value: One year of free online updates included with this productThere are today at least 285 ...
See all reports like this >>